Bio Rad Financials
BIO Stock | USD 325.58 1.89 0.58% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.13 | 0.1361 |
|
| |||||
Current Ratio | 6.12 | 5.8308 |
|
|
Investors should never underestimate Bio Rad's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bio Rad's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bio Rad Laboratories.
Cash And Equivalents |
|
Bio | Select Account or Indicator |
Understanding current and past Bio Rad Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bio Rad's financial statements are interrelated, with each one affecting the others. For example, an increase in Bio Rad's assets may result in an increase in income on the income statement.
Bio Rad Earnings Geography
Bio Rad Stock Summary
Bio Rad competes with Tandem Diabetes, DexCom, Inspire Medical, Penumbra, and CONMED. Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 8200 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | New York Stock Exchange |
ISIN | US0905722072 |
CUSIP | 090572207 |
Location | California; U.S.A |
Business Address | 1000 Alfred Nobel |
Sector | Life Sciences Tools & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.bio-rad.com |
Phone | 510 724 7000 |
Currency | USD - US Dollar |
Bio Rad Key Financial Ratios
Return On Equity | -0.0979 | ||||
Profit Margin | (0.30) % | ||||
Operating Margin | 0.1 % | ||||
Price To Sales | 3.54 X | ||||
Revenue | 2.67 B |
Bio Rad Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Other Current Liab | 158.5M | 354.0M | 404.9M | 312.2M | 301.6M | 316.6M | |
Net Debt | (220.9M) | (648.1M) | (459.8M) | 764.0M | 1.0B | 1.1B | |
Retained Earnings | 5.5B | 9.3B | 13.5B | 9.9B | 9.3B | 9.7B | |
Cash | 660.7M | 662.2M | 470.8M | 434.2M | 404.0M | 257.1M | |
Net Receivables | 392.7M | 419.4M | 423.5M | 494.6M | 489.0M | 272.4M | |
Inventory | 554.0M | 622.3M | 572.2M | 719.3M | 780.5M | 819.5M | |
Other Current Assets | 113.3M | 97.5M | 124.8M | 153.3M | 171.7M | 92.3M | |
Total Liab | 2.3B | 3.1B | 4.1B | 3.9B | 3.6B | 3.7B | |
Total Current Assets | 2.2B | 2.1B | 2.0B | 3.2B | 3.0B | 3.2B | |
Short Term Debt | 426.2M | 38.3M | 36.9M | 36.8M | 40.9M | 33.9M | |
Accounts Payable | 287.1M | 139.5M | 141.9M | 135.0M | 144.6M | 116.6M | |
Intangible Assets | 145.5M | 199.5M | 253.9M | 332.1M | 320.5M | 188.7M | |
Other Assets | 40.3M | 13K | 82K | 94.6M | 85.1M | 71.4M | |
Long Term Debt | 13.6M | 12.3M | 10.5M | 1.2B | 1.2B | 1.3B | |
Good Will | 264.1M | 291.9M | 347.3M | 406.5M | 413.6M | 339.1M | |
Treasury Stock | (38.4M) | (99.9M) | (106.3M) | (263.6M) | (237.2M) | (225.4M) | |
Other Liab | 1.2B | 2.4B | 3.4B | 2.0B | 2.3B | 2.4B | |
Net Tangible Assets | 5.8B | 9.9B | 13.1B | 9.2B | 10.6B | 11.1B | |
Capital Surpluse | 410.0M | 429.4M | 441.7M | 447.5M | 514.6M | 366.5M |
Bio Rad Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 23.4M | 21.9M | 1.6M | 38.1M | 49.4M | 51.9M | |
Total Revenue | 2.3B | 2.5B | 2.9B | 2.8B | 2.7B | 1.4B | |
Gross Profit | 1.3B | 1.4B | 1.6B | 1.6B | 1.4B | 769.3M | |
Operating Income | 229.7M | 411.0M | 489.4M | 482.6M | 383.8M | 403.0M | |
Ebit | 229.7M | 4.9B | 5.5B | (4.7B) | (800.7M) | (760.6M) | |
Ebitda | 390.0M | 5.1B | 5.6B | (4.5B) | (608.3M) | (577.9M) | |
Cost Of Revenue | 1.1B | 1.1B | 1.3B | 1.2B | 1.2B | 1.3B | |
Income Before Tax | 2.3B | 4.9B | 5.4B | (4.7B) | (850.1M) | (807.6M) | |
Net Income | 1.8B | 3.8B | 4.3B | (3.6B) | (637.3M) | (605.5M) | |
Income Tax Expense | 502.4M | 1.1B | 1.2B | (1.1B) | (212.8M) | (202.1M) | |
Research Development | 202.7M | 226.6M | 271.7M | 256.9M | 226.9M | 161.8M | |
Tax Provision | 502.4M | 1.1B | 1.2B | (1.1B) | (27.9M) | (26.5M) | |
Interest Income | 30.5M | 4.5B | 4.9B | 58M | 96.4M | 91.6M | |
Net Interest Income | 7.1M | (21.9M) | (1.6M) | 19.9M | 47.6M | 50.0M |
Bio Rad Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 24.2M | (52.1M) | 46.1M | (158.8M) | (46.3M) | (44.0M) | |
Change In Cash | 228.5M | 4.5M | (196.0M) | (36.6M) | (30.2M) | (28.7M) | |
Free Cash Flow | 359.4M | 476.4M | 535.7M | 80.3M | 218.3M | 229.2M | |
Depreciation | 134.2M | 138.1M | 133.8M | 137.3M | 192.4M | 202.0M | |
Other Non Cash Items | (1.5B) | (3.4B) | (3.7B) | 5.3B | 1.1B | 1.1B | |
Capital Expenditures | 98.5M | 98.9M | 120.8M | 114.2M | 156.7M | 84.5M | |
Net Income | 1.8B | 3.8B | 4.2B | (3.6B) | (637.3M) | (605.5M) | |
End Period Cash Flow | 662.7M | 667.1M | 471.1M | 434.5M | 404.4M | 286.4M | |
Change To Netincome | (2.0B) | (3.5B) | (3.8B) | 5.3B | 4.7B | 5.0B | |
Change Receivables | 31.7M | 21.5M | 35.3M | 68.2M | 78.4M | 82.3M | |
Net Borrowings | (1.1M) | (426.9M) | (3.0M) | 1.2B | 1.4B | 1.4B | |
Investments | (119.3M) | 119.6M | (538.2M) | (994.2M) | (110.5M) | (116.1M) |
Bio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio Rad's current stock value. Our valuation model uses many indicators to compare Bio Rad value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Rad competition to find correlations between indicators driving Bio Rad's intrinsic value. More Info.Bio Rad Laboratories is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Bio Rad's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Rad's earnings, one of the primary drivers of an investment's value.Bio Rad's Earnings Breakdown by Geography
Bio Rad Laboratories Systematic Risk
Bio Rad's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bio Rad volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Bio Rad Laboratories correlated with the market. If Beta is less than 0 Bio Rad generally moves in the opposite direction as compared to the market. If Bio Rad Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bio Rad Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bio Rad is generally in the same direction as the market. If Beta > 1 Bio Rad moves generally in the same direction as, but more than the movement of the benchmark.
Bio Rad Thematic Clasifications
Bio Rad Laboratories is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Measuring and Control Equipment | View |
Today, most investors in Bio Rad Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Rad's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bio Rad growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Bio Rad November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bio Rad help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio Rad Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio Rad Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio Rad's daily price indicators and compare them against related drivers.
Downside Deviation | 2.33 | |||
Information Ratio | (0.02) | |||
Maximum Drawdown | 16.89 | |||
Value At Risk | (3.62) | |||
Potential Upside | 2.94 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.09) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.